Strong unit and revenue growth driven by customer acquisition, expansion, and Realm-X adoption through premium tiers and value added servicesSANTA BARBARA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ: APPF) ("AppFolio" or the "Company"), a technology leader powering the future of the real estate industry, today announced its financial results for the third quarter ended September 30, 2025. "I'm pleased with our third quarter results, as we continue to win in the market. We are expanding ...

EL MONTE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that it will report its financial results for the third quarter and nine months ended September 30, 2025 after the market closes on Thursday, November 6, 2025. The Company will host a conference call to discuss its financial results on the same day at 6:00 PM Eastern Time. To access the ...

Core Insights - TFI International Inc. reported a decrease in total revenue for Q3 2025, amounting to $1.97 billion, down from $2.18 billion in the same period last year, primarily due to reduced volumes from weaker end market demand [4][8] - The company generated over $570 million in free cash flow year-to-date, exceeding the previous year's nine-month figure, which enhances its ability to operate and invest strategically [2][4] - The Board of Directors approved a 4% increase in the quarterly dividend to $0.47 per share, reflecting a commitment to returning excess capital to shareholders [6][18] Financial Highlights - Total revenue for Q3 2025 was $1,968.7 million, compared to $2,184.6 million in Q3 2024, marking an 11% decrease [4][8] - Adjusted EBITDA for Q3 2025 was $305.4 million, down from $357.2 million in Q3 2024 [32] - Net income for Q3 2025 was $84.7 million, compared to $125.9 million in Q3 2024, with diluted EPS decreasing from $1.48 to $1.02 [5][10] Segment Performance - The Less-Than-Truckload segment saw a revenue decrease of 11%, Truckload decreased by 7%, and Logistics decreased by 14% compared to Q3 2024 [7] - Operating income decreased by 19% for Less-Than-Truckload, 25% for Truckload, and 36% for the Logistics segment [7] Cash Flow and Shareholder Returns - Net cash from operating activities for Q3 2025 was $255.4 million, down from $351.1 million in Q3 2024 [13] - The company returned $104.8 million to shareholders during the quarter, including $37.3 million in dividends and $67.4 million in share repurchases [15] Guidance - For Q4 2025, TFI International expects adjusted diluted EPS to be in the range of $0.80 to $0.90, influenced by lower deliveries in the Logistics segment and weak overall freight demand [16]

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine compan ...

MENLO PARK, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the third quarter of fiscal year 2025 ended October 3, 2025. “Exponent delivered a strong third quarter, achieving double digit net revenue growth that reflects the strength of our diversified portfolio and our ability to deliver value across industries,” stated Dr. Catherine Corrigan, President and Chief Executive Officer. “Increasing demand for dispute-related work drove robust growth i ...

Highlights† Reported revenue of $384.2 million, up 13.0%Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectivelyGAAP operating margin of 11.1%, compared to 11.0% in prior year periodNon-GAAP operating margin* of 19.7%, compared to 19.2% in prior year periodGAAP EPS $0.46, down 3.0%Non-GAAP EPS* $0.92, up 6.7%Free cash flow* generation of $141.6 million over first nine months of 2025, up 17.6% year-over-year † Comparisons above are calculated for the current quart ...

IRVINE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Shimmick Corporation (“Shimmick”) (Nasdaq: SHIM), a national leader in complex infrastructure solutions, today announced that the company will release its third quarter 2025 financial results after market close on Thursday, November 13, 2025. Shimmick will also host a video webcast conference call to discuss those results at 4:30 p.m. Eastern Time on the same day. The conference call will be live-streamed via the Company’s Investor Relations website (https:/ ...

Core Insights - iRhythm Technologies reported a strong performance in Q3 2025, with revenue increasing by 30.7% year-over-year, reflecting the scalability of its platform and growing adoption of its technology across the healthcare ecosystem [3][4]. Financial Performance - Revenue for Q3 2025 was $192.9 million, up from $147.5 million in Q3 2024, driven by increased demand for Zio services [4]. - Gross profit for Q3 2025 was $137.1 million, a 35.1% increase from $101.5 million in Q3 2024, with a gross margin of 71.1%, improving by 230 basis points year-over-year [5]. - Operating expenses for Q3 2025 were $145.6 million, down from $151.8 million in Q3 2024, with adjusted operating expenses at $141.4 million compared to $143.8 million in the prior year [6]. - The net loss for Q3 2025 was $5.2 million, or a diluted loss of $0.16 per share, significantly improved from a net loss of $46.2 million, or a diluted loss of $1.48 per share, in Q3 2024 [7][8]. Cash Flow and Guidance - iRhythm achieved record free cash flow generation in Q3 2025 and anticipates being free cash flow positive for the entire year for the first time in its history [3]. - The company projects full-year 2025 revenue between $735 million to $740 million, with an expected adjusted EBITDA margin of approximately 8.25% to 8.75% [9]. Market Position and Innovations - The company continues to expand into primary care and population health programs, with progress in EHR integration and new clinical evidence supporting its leadership in proactive cardiac monitoring [3]. - iRhythm is advancing its innovation pipeline, including the submission of its next-generation Zio MCT solution to the FDA and early work in sleep diagnostics [3]. Research and Clinical Evidence - Recent publications, including the AVALON real-world evidence and AMALFI randomized clinical trial, reinforce the clinical value proposition of iRhythm's Zio long-term continuous monitoring service [7].

MINNEAPOLIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off, insolvency and active consumer accounts, today announced that it will release financial results for the third quarter 2025 after the market close on Thursday, November 13, followed by a webcast at 5:00 pm Eastern Time that day to discuss the Company’s results. The live webcast and archived replay can be accessed in the investor relations section of ...

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/4jh5a49o Participants may a ...